Bain Capital Life Sciences Investors’s Spyre Therapeutics SYRE Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-213,908	Closed	-$1.55M	–	33
2023 Q1	$1.55M	Hold	213,908	–	–	0.19%	32
2022 Q4	$2.41M	Hold	213,908	–	–	0.27%	32
2022 Q3	$2.81M	Hold	213,908	–	–	0.34%	33
2022 Q2	$2.7M	Buy	213,908 +100,000	+88%	+$3.5M	0.32%	35
2022 Q1	$6.55M	Hold	113,908	–	–	0.64%	27
2021 Q4	$13.5M	Hold	113,908	–	–	1.07%	22
2021 Q3	$22.6M	Buy	113,908 +5,908	+5%	+$1.03M	1.4%	17
2021 Q2	$18.8M	Hold	108,000	–	–	1.23%	19
2021 Q1	$21.4M	Hold	108,000	–	–	1.21%	17
2020 Q4	$21.2M	Hold	108,000	–	–	1.33%	15
2020 Q3	$19.1M	Hold	108,000	–	–	1.78%	13
2020 Q2	$25M	Buy	+108,000	New	+$20.6M	2.62%	8

Other funds holding SYRE

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bain Capital Life Sciences Investors's SYRE Position: Q2 2023 in Review

Bain Capital Life Sciences Investors sold out of Spyre Therapeutics (SYRE) in Q2 2023, closing a stake of 213,908 shares — an estimated $1.55M sold.

Bain Capital Life Sciences Investors first reported a position in SYRE in Q2 2020 and held it in 12 quarters. The position peaked at $25M in Q2 2020. 43 funds tracked by Wall St. Rank hold SYRE as of Q2 2023.

Bain Capital Life Sciences Investors reported no remaining Spyre Therapeutics position as of Q2 2023 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 213,908 Spyre Therapeutics shares in Q2 2023, an estimated $1.55M.
Bain Capital Life Sciences Investors first reported a position in Spyre Therapeutics in Q2 2020 and held it in 12 quarters.
Bain Capital Life Sciences Investors's Spyre Therapeutics position peaked at $25M in Q2 2020.
43 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2023.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2023, filed 14 Aug 2023.